China’s biotechnology industry is currently experiencing a supply bottleneck for primate experimental models, which are essential for drug testing and development. According to Joinn Laboratories, a major player in the Chinese biotech space, the recent recovery in fundraising and the increase in drug out-licensing deals have triggered a sharp rise in demand for these animals.

While the biotech sector is seeing a resurgence in activity, the limited availability of laboratory monkeys threatens to hinder the speed at which new innovative drugs can be brought to market. Primate models are considered a gold standard in pre-clinical trials, and the current scarcity is forcing companies to navigate a tighter supply chain. The situation highlights the direct link between the financial health of the pharmaceutical sector and the physical infrastructure required to support its growth. As biotech firms continue to secure capital, the pressure on the supply of these research animals is expected to persist, potentially creating a long-term challenge for the industry's expansion goals.